A new SARS-CoV-2 variant, Pirora (BA.2.86), has been detected worldwide and is causing concern due to its high mutation rate
Researchers at the La Jolla Institute for Immunology are using immune epitope databases to predict T-cell responses to Pirora, suggesting that past exposure to existing vaccines and variants like Omicron remains important and may have a preventive effect. Although the results are promising, they are still predictive and require further experimental validation. (Credit: SciTechDaily.com)
Utilization of bioinformatics
LJI scientists are using bioinformatics to predict how T cells will adapt to fight the highly mutated Pirora mutant. In August, researchers discovered a new SARS-CoV-2 ‘Variants of concern’ in patients in Israel and Denmark. Since then, this variant has been called BA.2.86 or “Pirola” and has spread all over the world. Pirola’s mutant species is highly mutated, so caution is advised. In fact, Pirora has mutated similarly to the Omicron variant when compared to the earlier SARS-CoV-2 variants that were included in the first vaccinations. As Pyrolla spreads, researchers at La Jolla Immunology Institute (LJI) COVID-19 (new coronavirus infection) Vaccines (or previous SARS-CoV-2 infection) can still protect people from severe disease.
“The concern is that virus With so many mutations, T-cell immunity will ‘escape’,” says LJI Professor Alessandro Sette, Ph.D. in Biological Sciences. New research is currently being conducted Cell hosts and microorganisms This suggests that T cells can accurately detect mutations in pyrola and find their targets.
“Our analysis suggests there is positive news,” says LJI research assistant professor Dr. Alba Grifoni. “It appears that past exposure to Omicron, or vaccination with the new bivalent vaccine, may provide a person with T cells that can ‘catch up’ and generate a specific response to fight Pyrrha. ” LJI Professor Alessandro Sette, Doctor of Biological Sciences
(Credit: La Jolla Institute of Immunology)
Next step
Grifoni emphasizes that these findings are predictive and not observations based on actual pylora infections. Still, she thinks it’s important to see how these “in silico” (in silico) predictions are reflected in recent real-world research. “Although we still need experimental validation, we have established several collaborations around the world and are talking about this issue as we study it,” says Grifoni. Sette added that even with the Pirora variant, many people are still vulnerable to SARS-COV-2 infection. “That’s why people should still get vaccinated, especially the latest vaccines.” The researchers are currently collecting experimental data to learn more about T cell responses to the mutant strains and further strengthen their predictive tools. Griffoni is particularly interested in understanding exactly how people who have received a bivalent vaccine booster or a “breakthrough” infection will mount a T-cell response against future variants.
Reference:
“Existing SARS-2-specific T cells are predicted to cross-recognize BA.2.86,” Alessandro Sette, John Sidney, and Alba Grifoni, December 8, 2023. Cell hosts and microorganisms.DOI: 10.1016/j.chom.2023.11.010 The study, “Existing SARS-2-specific T cells are predicted to mutually recognize BA.2.86,” also includes study author John Sidney. This research was supported by: National Institutes of HealthNational Institute of Allergy and Infectious Diseases (Contract No. 75N93021C00016 and Contract No. 75N93019C00001)
Source: scitechdaily.com
